Clinical Trial: Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Brief Summary: The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Detailed Summary:
Sponsor: Capital Medical University

Current Primary Outcome: bleb vascular change [ Time Frame: one day, one week, one month ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Capital Medical University

Dates:
Date Received: December 29, 2008
Date Started: December 2008
Date Completion: May 2009
Last Updated: December 29, 2008
Last Verified: December 2008